Drug Profile

PORT 8

Alternative Names: PORT-8; TT-53

Latest Information Update: 28 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Impetis Biosciences
Developer Portage Biotech
Class Antineoplastics; Small molecules
Mechanism of Action Adenosine A2A receptor antagonists; Adenosine A2B receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Solid tumours

Most Recent Events

28 Aug 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA
05 Aug 2022 Stimunity establishes CRADA with National Cancer Institute for the development of adenosine in Cancer before August 2022
19 Aug 2021 Tarus Therapeutics plans to submit an IND application for TT 53, in the first quarter of 2022 (Tarus Therapeutics pipeline, August 2021)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com